Comparison 4. Ciclesonide versus Fluticasone (dose ratio 1:2).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Exacerbations requiring oral steroids	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
1.1 Children	0		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Adults	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Change from baseline in FEV1	1		L (Fixed, 95% CI)	Totals not selected
2.1 Children	0		L (Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 Adults	1		L (Fixed, 95% CI)	0.0 [0.0, 0.0]
3 Endpoint FEV1 (Litres)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3.1 Children	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
3.2 Adults	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Endpoint FEV1 predicted (%)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.1 Children	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
4.2 Adults	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
5 Change in FVC	1		L (Fixed, 95% CI)	Totals not selected
5.1 Children	0		L (Fixed, 95% CI)	0.0 [0.0, 0.0]
5.2 Adults	1		L (Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Endpoint day symptoms	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6.1 Children	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.2 Adults	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Endpoint night symptoms	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
7.1 Children	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.2 Adults	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 Rescue medication use (puffs/d)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8.1 Children	0		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
8.2 Adults	1		Mean Difference (IV, Fixed, 95% CI)	0.0 [0.0, 0.0]
9 Change in clinic PEF	1		L/min (Fixed, 95% CI)	Totals not selected
9.1 Children	0		L/min (Fixed, 95% CI)	0.0 [0.0, 0.0]
9.2 Adults	1		L/min (Fixed, 95% CI)	0.0 [0.0, 0.0]
10 Change in rescue medication	1		puffs/d (Fixed, 95% CI)	Totals not selected
10.1 Children	0		puffs/d (Fixed, 95% CI)	0.0 [0.0, 0.0]
10.2 Adults	1		puffs/d (Fixed, 95% CI)	0.0 [0.0, 0.0]
11 Adverse events	2	1017	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.83, 1.16]
11.1 Children	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
11.2 Adults	2	1017	Risk Ratio (M‐H, Fixed, 95% CI)	0.98 [0.83, 1.16]
12 Nasopharyngitis	2	1017	Risk Ratio (M‐H, Fixed, 95% CI)	1.17 [0.72, 1.91]
12.1 Children	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
12.2 Adults	2	1017	Risk Ratio (M‐H, Fixed, 95% CI)	1.17 [0.72, 1.91]
13 Withdrawals	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
13.1 Children	0		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
13.2 Adults	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
14 Withdrawal (adverse events)	2	1017	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.24, 1.59]
14.1 Children	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
14.2 Adults	2	1017	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.24, 1.59]